https://doi.org/10.4081/hmr.v3i1.533

Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 293
PDF: 404
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

O Shonukan
support@pagepress.org
AH Dantzig
S Kloeker-Rhoades
I Garcia-Ribas
Gemcitabine (Gemzar) is a fluorinated pyrimidine nucleoside analogue that demonstrated a high schedule-dependency during its development for the therapy of diverse malignancies. This schedule- dependency may depend on the steps that are required to induce cytotoxic activity, and include intracellular uptake by specific nucleoside transporters and the effect on cancer cells at the G1 and S phases of the cell cycle. Gemzar is currently approved to be administered weekly at 1000-1250 mg/m2, either as a single agent or in combination with other agents for the therapy of several solid tumors. Gemcitabine also has activity in Hodgkin’s and in several types of non-Hodgkin’s lymphoma including some subsets of peripheral T cell lymphoma.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Shonukan, O., Dantzig, A., Kloeker-Rhoades, S., & Garcia-Ribas, I. (2009). Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.533
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).